While the United States awaits the launch of its first biosimilar rituximab, other regulatory jurisdictions have biosimilars referencing Rituxan already available on the market. One such product, available in South America, the Middle East, and Africa, is RTXM83, developed by drug maker mAbxience.
While the United States awaits the launch of its first biosimilar rituximab, other regulatory jurisdictions have biosimilars referencing Rituxan already available on the market. One such product, available in South America, the Middle East, and Africa, is RTXM83, developed by drug maker mAbxience.
A newly published study discusses the physiochemical and biological characterization exercises that were used to demonstrate biosimilarity between RTXM83 and its reference and led to the product’s eventual regulatory approval in multiple territories.1
According to the study’s authors, primary and higher-order protein structures were analyzed using techniques that included peptide mapping with liquid chromatography—electrospray ionization–tandem mass spectrometry (MS), fluorescence spectroscopy and circular dichroism, and microdifferential scanning calorimetry.
Charge variants were determined by cation-exchange chromatography and capillary isoelectric focusing, whereas glycosylation and glycoform distribution were analyzed using MS, normal phase high-performance liquid chromatography, and high-performance anion-exchange chromatography with pulsed amperometric detection.
Size variants were evaluated by size-exclusion chromatography, sedimentation velocity analytical ultracentrifugation, dynamic light scattering, and capillary electrophoresis—sodium dodecyl sulfate.
Biological characterization included binding assays for complement C1q, CD20, and multiple Fc receptors, along with a potency determination for in vitro apoptosis induction, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated cytotoxicity (ADCC).
The researchers write that the biosimilar and the reference showed identical primary sequences and disulfide bridge patterns. There was also similarity among higher-order structures, posttranslational modification profiles, and levels of purity.
Functional studies showed that the biosimilar and its reference were similar in the 3 known mechanisms of action of rituximab: apoptosis induction, CDC, and ADCC. Binding affinities to CD20, complement component C1q, and Fc receptors were also equivalent.
The researchers concluded that the biosimilar and the reference product were similar in all critical quality attributes.
The biosimilar was also investigated in a phase 3 clinical study in which it was compared to the reference rituximab in 241 patient with diffuse large B-cell lymphoma.2
In the study, a difference of 3.9% in favor of the biosimilar was observed in the response rate (comprising complete response plus partial response) after 6 cycles of treatment. Safety assessments showed no obvious differences in safety between the biosimilar and the reference, and a low and similar incidence of anti-drug antibodies was observed in both arms.
Pharmacokinetics (PK) were assessed using a population PK approach, and systemic exposure was assessed at cycle 1 and steady state at cycle 6; the PK assessment comprised 5341 samples from 251 individuals, and the geometric least square means ratios fell within the prespecified equivalence margins of 80% to 125%. The pharmacodynamic profile (in terms of time of onset, magnitude, and duration of response) was also similar between RTXM83 and its reference; taken together, these data led the authors of the phase 3 study to conclude that the biosimilar and the reference product were highly similar.
Reference
1. Cerutti ML, Pesce A, Bés C, Seigelchifer M. Physiochemical and biological characterization of RTXM83, a new rituximab biosimilar [published online March 29, 2019]. BioDrugs. doi: 10.1007/s40259-019-00349-2.
2. Candelaria M, Gonzalez DE, Beniwal SK, et al. A randomized, double-blind, phase 3 study comparing proposed biosimilar rituximab (RTXM83) versus reference rituximab, both in combination with CHOP, in the first line treatment of patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2017;130:1556. www.bloodjournal.org/content/130/Suppl_1/1556.
BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimilars
December 10th 2024The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a setback for biosimilar developers, as it preserves patent prosecution practices that favor originator companies and increases costs for biosimilar competition, according to Sarfaraz K. Niazi, PhD.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Pertuzumab Biosimilar Shows Promise in HER2-Positive Breast Cancer Treatment
December 9th 2024The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Omalizumab Biosimilar Shows Equivalent Efficacy as Multiple Sclerosis Treatment
November 26th 2024The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and efficacy in treating relapsing multiple sclerosis over 96 weeks.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.